Novartis2d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
The Lancet2d
Advancing policies for rare diseases in Europe
Fostering dialogue between neurologists, researchers, patient representatives, and policymakers is an important step towards ...
JD Supra3d
Early benefit assessment of medicinal products in Germany – first adaptions to AMNOG implementing the EU HTA Regulation
HTA as described by the HTA Regulation is the multidisciplinary scientific evidence-based process that allows to determine the relative effectiveness of new or existing health technologies. HTA is a ...